# A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine

> **NCT01031966** · PHASE2 · COMPLETED · sponsor: **sigma-tau i.f.r. S.p.A.** · enrollment: 120 (actual)

## Conditions studied

- END STAGE RENAL DISEASE

## Interventions

- **BIOLOGICAL:** MF59 adjuvanted H1N1 influenza monovalent vaccine
- **DRUG:** Thymosin alpha 1
- **DRUG:** Thymosin alpha 1

## Key facts

- **NCT ID:** NCT01031966
- **Lead sponsor:** sigma-tau i.f.r. S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-05
- **Final completion:** 2010-07
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2012-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01031966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01031966, "A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01031966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*